All News
Topical therapies take centre stage
Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium.
Read ArticleLinks:
Methotrexate Monitoring (5.13.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.
Read ArticleWiki Guidelines Approach to Pyogenic Osteomyelitis
A crowd sourced, WikiGuidelines approach to clinical treatment guideline development for pyogenic osteomyelitis yielded 7 important clinical questions, 2 clear treatment recommendations and 5 topic reviews to inform future treatment or investigations.
Read ArticleArthritis Predicts Hepatic Fibrosis in Hemochromatosis
Mayo Clinic Proceedings reports the results of a retrospective, cross-sectional of patients with HFE hemochromatosis showing that advanced hepatic fibrosis is primarily seen in those with arthritis due to HFE hemochromatosis.
Read ArticleTheDaoIndex KDAO2011 ( View Tweet)
Links:
ACR Guidelines for the Treatment of Systemic Juvenile Idiopathic Arthritis
The ACR has updated its clinical guidelines for the management of juvenile idiopathic arthritis (JIA), with this update focusing on oligoarthritis, TMJ arthritis, and systemic JIA (with and without macrophage activation syndrome); only the latter, systemic JIA recommendations are reported he
Read ArticlePositive Results from the DOA (Duloxetine in OsteoArthritis) Study
A pragmatic, open-label trial of osteoarthritis (OA) patients demonstrated that adding duloxetine treatment seems to be beneficial for end-stage knee OA patients with neuropathic-like symptoms (at risk of central sensitization).
Read ArticleLinks:
Why Would Hand OA Be Less Severe in Black People?
Osteoarthritis (OA) of the hand was less severe according to objective and pain-related markers in Black patients versus those of other racial/ethnic groups after adjustment for known risk factors, researchers found.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
Links:
X-Linked Hypophophatemia - Survey Results
The July 2021 RheumNow “Live Vote” surveyed US and non-US rheumatologists on their knowledge and practices when dealing with the bone disorder, X-linked hypophosphatemia (XLH).
Read ArticleLinks:
Fracture Risk with Osteoporosis Drug Holidays
While bisphosphonate drug holidays are recommended, there are few comparative studies.
Read ArticleBest of 2021: Jack of All Subspecialties
It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen journal articles, news reports and questions + cases.
Read ArticleBest of 2021: Tofacitinib Safety Concerns
Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.
Read ArticleBest of 2021: EULAR Guidelines on Intraarticular Therapy
EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)